Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Français Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Weak Interaction

Raltegravir (RAL)

Regorafenib

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied. Regorafenib is metabolized by CYP3A4 and UGT1A9. Raltegravir is metabolized by UGT1A1 and does not inhibit or induce CYP enzymes. Regorafenib and its metabolites inhibit UGT1A1 and could increase raltegravir exposure, although to an extent that does not warrant a dose adjustment.

Description:

(See Summary)

View all available interactions with Raltegravir (RAL) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2025 The University of Liverpool. All rights reserved.